muhammadhafeezmalik
SENIOR MEMBER
- Joined
- Jan 21, 2015
- Messages
- 5,417
- Reaction score
- -17
- Country
- Location
Govt allows rise in prices of 94 life-saving drugs
• Reduces cost of Remdesivir injection
• Approves shutting down of power projects running in losses
• Minister says circular debt in power sector has gone up to Rs2.1tr
ISLAMABAD: The federal cabinet on Tuesday approved increase in prices of 94 life-saving drugs to ensure their availability in the market, and brought down the price of Remdesivir 100mg injection, used in Covid-19 treatment, from Rs10,873 to Rs8,244.
The meeting, which was presided over by Prime Minister Imran Khan, took a number of other important decisions related to energy crisis in the country, circular debt in the power sector and the anti-rape bill.
“The cabinet allowed increase in the prices of those drugs which are short in the market as their manufacturers have stopped their production due to losses,” Special Assistant to the Prime Minister on Health Dr Faisal Sultan said in a joint press conference with Information Minister Shibli Faraz after the cabinet meeting.
Dr Sultan said prices of most of the 94 drugs had not been increased for a decade due to which manufacturers stopped their production, causing their shortage in the market.
“When these drugs are not available in the market, patients are compelled to use costly smuggled drugs,” the special assistant said.
“For instance, if the price of a drug is Rs10, we have increased it to Rs15. Apparently it is a 50pc increase but we have to save people from buying similar (smuggled) drugs at a cost of Rs300 or above,” he added.
When Dawn asked Dr Sultan why the government believed by increasing prices of items, their availability in the market would be ensured as seen in the case of wheat flour and sugar, he said the government could not ensure availability of life-saving drugs by force because drug manufacturers always employed various methods to stop production if they were pressured to reduce prices.
The cabinet also allowed the import of life-saving drugs as well as anti-cancer and cardiac medicines not registered in Pakistan, exempting them from the ban.
If a company stops manufacturing some medicines, claiming that its production has become non-viable due to high cost of production and raw material, its price can be increased as a special case which is called a ‘hardship case’.
The Ministry of National Health Services (NHS) had moved the matter before the federal cabinet after some medicines, including the one used for cataract and by soldiers deployed in Siachen, had become short.
According to an official statement issued by the health ministry, in response to long-term shortages of some key or life-saving medicines, the federal cabinet on Tuesday allowed rationalising prices of drugs that had been reported to be in short supply due to unrealistically low prices.
This change was approved for drugs that fell in the ‘hardship category’ on the recommendation of the Drug Pricing Committee under the Drugs Pricing Policy 2018.
Some of the life-saving drugs whose prices have been allowed to increase include Furosemide injections (for emergency use in high blood pressure), Acetazolamide tablets (glaucoma), Hydralazine tablets (for lowering blood pressure), Carbamazepine tablets and suspension (epilepsy), Atropine Sulphate injection (used in emergencies), Magnesium Sulphate (used to treat seizures due to pre-eclampsia during pregnancy), Hydroxyurea, Daunorubicin, Bleomycin (used in treatment of cancer), Nitroglycerin and Glyceryl Trinitrate (emergency heart medicines) and anti-rabies vaccine.
“As an example, the price of Acetazolamide tablets has been Rs60.45 for a pack of 30 tablets for over a decade, despite increase in the cost of raw material needed to produce this drug in the international market, devaluation of rupee, increase in the price of packaging material and reduced volume of usage compared to the past. What it means is that this drug, which is not commonly used but is nevertheless essential in some clinical situations, has been available only on the black market, at greatly inflated prices,” the health ministry statement said.
An official of the NHS ministry, requesting not to be quoted, said the cabinet also considered the grant of exemption from section 23(1)(a)(VII) of the Drugs Act 1976.
“According to the section no medicine can be sold in Pakistan without its registration with the Drug Regulatory Authority of Pakistan (Drap). However, with the exemption health facilities or hospitals will be allowed to purchase medicines from the international market and use them for their patients. A Statutory Regulatory Order will be issued so that the medicines would be available under the right to medicine, he said.
• Reduces cost of Remdesivir injection
• Approves shutting down of power projects running in losses
• Minister says circular debt in power sector has gone up to Rs2.1tr
ISLAMABAD: The federal cabinet on Tuesday approved increase in prices of 94 life-saving drugs to ensure their availability in the market, and brought down the price of Remdesivir 100mg injection, used in Covid-19 treatment, from Rs10,873 to Rs8,244.
The meeting, which was presided over by Prime Minister Imran Khan, took a number of other important decisions related to energy crisis in the country, circular debt in the power sector and the anti-rape bill.
“The cabinet allowed increase in the prices of those drugs which are short in the market as their manufacturers have stopped their production due to losses,” Special Assistant to the Prime Minister on Health Dr Faisal Sultan said in a joint press conference with Information Minister Shibli Faraz after the cabinet meeting.
Dr Sultan said prices of most of the 94 drugs had not been increased for a decade due to which manufacturers stopped their production, causing their shortage in the market.
“When these drugs are not available in the market, patients are compelled to use costly smuggled drugs,” the special assistant said.
“For instance, if the price of a drug is Rs10, we have increased it to Rs15. Apparently it is a 50pc increase but we have to save people from buying similar (smuggled) drugs at a cost of Rs300 or above,” he added.
When Dawn asked Dr Sultan why the government believed by increasing prices of items, their availability in the market would be ensured as seen in the case of wheat flour and sugar, he said the government could not ensure availability of life-saving drugs by force because drug manufacturers always employed various methods to stop production if they were pressured to reduce prices.
The cabinet also allowed the import of life-saving drugs as well as anti-cancer and cardiac medicines not registered in Pakistan, exempting them from the ban.
If a company stops manufacturing some medicines, claiming that its production has become non-viable due to high cost of production and raw material, its price can be increased as a special case which is called a ‘hardship case’.
The Ministry of National Health Services (NHS) had moved the matter before the federal cabinet after some medicines, including the one used for cataract and by soldiers deployed in Siachen, had become short.
According to an official statement issued by the health ministry, in response to long-term shortages of some key or life-saving medicines, the federal cabinet on Tuesday allowed rationalising prices of drugs that had been reported to be in short supply due to unrealistically low prices.
This change was approved for drugs that fell in the ‘hardship category’ on the recommendation of the Drug Pricing Committee under the Drugs Pricing Policy 2018.
Some of the life-saving drugs whose prices have been allowed to increase include Furosemide injections (for emergency use in high blood pressure), Acetazolamide tablets (glaucoma), Hydralazine tablets (for lowering blood pressure), Carbamazepine tablets and suspension (epilepsy), Atropine Sulphate injection (used in emergencies), Magnesium Sulphate (used to treat seizures due to pre-eclampsia during pregnancy), Hydroxyurea, Daunorubicin, Bleomycin (used in treatment of cancer), Nitroglycerin and Glyceryl Trinitrate (emergency heart medicines) and anti-rabies vaccine.
“As an example, the price of Acetazolamide tablets has been Rs60.45 for a pack of 30 tablets for over a decade, despite increase in the cost of raw material needed to produce this drug in the international market, devaluation of rupee, increase in the price of packaging material and reduced volume of usage compared to the past. What it means is that this drug, which is not commonly used but is nevertheless essential in some clinical situations, has been available only on the black market, at greatly inflated prices,” the health ministry statement said.
An official of the NHS ministry, requesting not to be quoted, said the cabinet also considered the grant of exemption from section 23(1)(a)(VII) of the Drugs Act 1976.
“According to the section no medicine can be sold in Pakistan without its registration with the Drug Regulatory Authority of Pakistan (Drap). However, with the exemption health facilities or hospitals will be allowed to purchase medicines from the international market and use them for their patients. A Statutory Regulatory Order will be issued so that the medicines would be available under the right to medicine, he said.
Govt allows rise in prices of 94 life-saving drugs
The prices of these drugs had not been increased for a decade causing a shortage in the market, says SAPM Dr Faisal Sultan.
www.dawn.com
